« Return to News | Drug Sponsors

Shire shows strong profits for Q1

Tuesday, May 3, 2011 01:09 PM

Shire Pharmaceuticals has strong results for the first quarter, with its attention-deficit hyperactivity disorder (ADHD) drugs driving growth, according to Pharma Times.

Net income came in at $211.3 million, up 27%, while revenues increased 19% to $972 million. Turnover was driven by the ADHD drug Vyvanse (lisdexamfetamine dimesylate), which grew 31% to $202.3 million, and Adderall XR (mixed amphetamine salts) brought in $111.2 million, up 21%. Another ADHD drug, Intuniv (guanfacine), had sales of $41.9 million.

Shire rare diseases portfolio also fared particularly well, with Replagal (agalsidase alfa) for Fabry disease increased 55% to $105.4 million. Vpriv (velaglucerase alfa) for Gaucher's disease, brought in $59 million, up 917. The Hunter Syndrome therapy Elaprase (idursulfase) rose 3% to $103.5 million.

As for Shire's other products, Pentasa (mesalamine) climbed 11% to $64.5 million, and the firm’s newer ulcerative colitis drug Lialda/Mezavant brought in $87.1 million, up 37%.

The company also revealed positive phase II data looking at Vyvanse as a potential adjunctive treatment in for the negative symptoms of schizophrenia. Plans for a study in binge eating disorder as well as the continuing phase III program looking at Vyvanse for major depressive disorder may be underway as well.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.